Morristown-based QPharma has named a new managing director.
Badal Shah will oversee development for key opinion leaders, or KOL, and targeting.
Shah already established a KOL and thought-leader engagement practice, according to the company, which provides compliance and commercial services to the life sciences industry.
His role now expands to take on more responsibilities for growth and business development in KOL engagement and health care practitioner-targeting business.
He also will lead the company’s efforts to grow its KOL practice in Europe, Latin America and Asia.
Shah will oversee two tools of QPharma’s flagship Titanium platform, a cloud-based suite of commercial and compliance tools.
They are Ti KOL, an application for identifying, profiling and mapping KOLs and the practitioners they influence, and Ti Target, which analyzes claims, referrals and prescribing data to help clients identify which physicians to target and engage for sampling and promotional activities
“Since joining the company, Badal has helped shape QPharma’s status as a leader in the KOL engagement and HCP targeting space,” CEO and President Patrick P. Den Boer said. “In this new role, he will continue to develop solutions that greatly enhance the commercial success of our life sciences clients.”
Shah is a pharmacist and Rutgers University science and business graduate, with a specialization in drug discovery and development.
Based in the Morristown headquarters, he is a member of the Advisory Board of Directors for the American Pharmacy Purchasing Alliance.